Conditioning chemo before CAR-T for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares two standard chemotherapy combinations (bendamustine or fludarabine plus cyclophosphamide) given before a CAR-T cell treatment to see which one helps the CAR-T cells work better and causes fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma, including transformed lymphoma or Richter's transformation
- You are 18 years or older
- You are planning to receive a commercially available CAR-T cell product
- You have not had other experimental drugs within the past 4 weeks
- You have not had bendamustine in the 3 months before leukapheresis (cell collection)
- You have not had a prior anti-CD19 CAR-T treatment within the last 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
This study looks at how the standard chemotherapy given before CAR T-cell therapy affects the treatment's success in people with large B-cell lymphoma that has come back or not responded to previous treatment. It may help doctors find the best way to prepare your body for CAR T-cells.
This trial tests whether giving a low dose of radiation to the whole body before receiving CAR T-cell therapy helps the treatment work better for people with certain types of lymphoma or multiple myeloma that have come back or not responded to earlier treatments.
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.